TGF-β receptor signaling pathways in angiogenesis; emerging targets for anti-angiogenesis therapy

Current Pharmaceutical Biotechnology

Volumn 12, Issue 12, 2011, Pages 2108-2120

  van Meeteren, Laurens A ^a   Goumans, Marie José ^a   ten Dijke, Peter ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

ALK1; Angiogenesis; Anti angiogenesis therapy; BMP; Cancer; Endoglin; Smad; TGF

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1; ACTIVIN RECEPTOR LIKE KINASE 1 FC FRAGMENT; ANGIOPOIETIN RECEPTOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BONE MORPHOGENETIC PROTEIN 2; ENDOGLIN; FIBROBLAST GROWTH FACTOR 2; GROWTH DIFFERENTIATION FACTOR 5; IMMUNOGLOBULIN FC FRAGMENT; PF 03446962; PROTEIN ANTIBODY; SMAD1 PROTEIN; SMAD2 PROTEIN; SMAD4 PROTEIN; SMAD5 PROTEIN; THALIDOMIDE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 3; TRC 105; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ADVANCED CANCER; ANGIOGENESIS; ANTIANGIOGENIC THERAPY; ARTICLE; BLEEDING; BREAST CANCER; CANCER PATIENT; CELL INTERACTION; CELL MIGRATION; CELL PROLIFERATION; CELL STIMULATION; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; EPITHELIUM CELL; GENE EXPRESSION; HUMAN; HYPERTENSION; KNOCKOUT MOUSE; LIGAND BINDING; MESENCHYME CELL; NONHUMAN; PHENOTYPE; PREECLAMPSIA; PROTEIN DOMAIN; PULMONARY HYPERTENSION; RENDU OSLER WEBER DISEASE; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; SOLID TUMOR; UNSPECIFIED SIDE EFFECT;

ANIMALS; ENDOTHELIUM, VASCULAR; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 80054761476     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920111798808338     Document Type: Article

References (130)

1. Adams, R. H.; Alitalo, K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat. Rev. Mol. Cell Biol., 2007, 8 (6), 464-478.
2. Carmeliet, P. Angiogenesis in health and disease. Nat. Med., 2003, 9 (6), 653-660.
3. Burri, P. H.; Hlushchuk, R.; Djonov, V. Intussusceptive angiogenesis: its emergence, its characteristics, and its significance. Dev. Dyn., 2004, 231 (3), 474-488.
4. Jakobsson, L.; Bentley, K.; Gerhardt, H. VEGFRs and Notch: a dynamic collaboration in vascular patterning. Biochem. Soc. Trans., 2009, 37 (Pt 6), 1233-1236.
5. Gerhardt, H.; Golding, M.; Fruttiger, M.; Ruhrberg, C.; Lundkvist, A.; Abramsson, A.; Jeltsch, M.; Mitchell, C.; Alitalo, K.; Shima, D.; Betsholtz, C. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J. Cell Biol., 2003, 161 (6), 1163-1177.
6. Olsson, A. K.; Dimberg, A.; Kreuger, J.; Claesson-Welsh, L. VEGF receptor signalling - in control of vascular function. Nat. Rev. Mol. Cell Biol., 2006, 7 (5), 359-371.
7. ten Dijke, P.; Arthur, H. M. Extracellular control of TGF-β signalling in vascular development and disease. Nat. Rev. Mol. Cell Biol., 2007, 8 (11), 857-869.
8. Moustakas, A.; Heldin, C. H. The regulation of TGF-β signal transduction. Development, 2009, 136 (22), 3699-3714.
9. Itoh, S.; ten Dijke, P. Negative regulation of TGF-β receptor/Smad signal transduction. Curr. Opin. Cell Biol., 2007, 19 (2), 176-184.
10. Zhang, Y. E. Non-Smad pathways in TGF-β signaling. Cell Res., 2009, 19 (1), 128-139.
11. Shull, M. M.; Ormsby, I.; Kier, A. B.; Pawlowski, S.; Diebold, R. J.; Yin, M.; Allen, R.; Sidman, C.; Proetzel, G.; Calvin, D. Targeted disruption of the mouse transforming growth factor-β 1 gene results in multifocal inflammatory disease. Nature, 1992, 359 (6397), 693-699.
12. Kulkarni, A. B.; Huh, C. G.; Becker, D.; Geiser, A.; Lyght, M.; Flanders, K. C.; Roberts, A. B.; Sporn, M. B.; Ward, J. M.; Karlsson, S. Transforming growth factor β-1 null mutation in mice causes excessive inflammatory response and early death. Proc. Natl. Acad. Sci. USA, 1993, 90 (2), 770-774.
13. Letterio, J. J.; Geiser, A. G.; Kulkarni, A. B.; Roche, N. S.; Sporn, M. B.; Roberts, A. B. Maternal rescue of transforming growth factor-β 1 null mice. Science, 1994, 264 (5167), 1936-1938.
14. Kallapur, S.; Ormsby, I.; Doetschman, T. Strain dependency of TGF-β1 function during embryogenesis. Mol. Reprod. Dev., 1999, 52 (4), 341-349.
15. Dickson, M. C.; Martin, J. S.; Cousins, F. M.; Kulkarni, A. B.; Karlsson, S.; Akhurst, R. J. Defective haematopoiesis and vasculogenesis in transforming growth factor-β-1 knock out mice. Development, 1995, 121 (6), 1845-1854.
16. Bonyadi, M.; Rusholme, S. A.; Cousins, F. M.; Su, H. C.; Biron, C. A.; Farrall, M.; Akhurst, R. J. Mapping of a major genetic modifier of embryonic lethality in TGF β-1 knockout mice. Nat. Genet., 1997, 15 (2), 207-211.
17. Winnier, G.; Blessing, M.; Labosky, P. A.; Hogan, B. L. Bone morphogenetic protein-4 is required for mesoderm formation and patterning in the mouse. Genes Dev., 1995, 9(17), 2105-2116.
18. Zhang, H.; Bradley, A. Mice deficient for BMP2 are nonviable and have defects in amnion/chorion and cardiac development. Development, 1996, 122 (10), 2977-2986.
19. Urness, L. D.; Sorensen, L. K.; Li, D. Y. Arteriovenous malformations in mice lacking activin receptor-like kinase-1. Nat. Genet., 2000, 26 (3), 328-331.
20. Oh, S. P.; Seki, T.; Goss, K. A.; Imamura, T.; Yi, Y.; Donahoe, P. K.; Li, L.; Miyazono, K.; ten Dijke, P.; Kim, S.; Li, E. Activin receptor-like kinase 1 modulates transforming growth factor-β-1 signaling in the regulation of angiogenesis. Proc. Natl. Acad. Sci. USA, 2000, 97 (6), 2626-2631.
21. Roman, B. L.; Pham, V. N.; Lawson, N. D.; Kulik, M.; Childs, S.; Lekven, A. C.; Garrity, D. M.; Moon, R. T.; Fishman, M. C.; Lechleider, R. J.; Weinstein, B. M. Disruption of acvrl1 increases endothelial cell number in zebrafish cranial vessels. Development, 2002, 129 (12), 3009-3019.
22. Larsson, J.; Goumans, M. J.; Sjostrand, L. J.; van Rooijen, M. A.; Ward, D.; Leveen, P.; Xu, X.; ten Dijke, P.; Mummery, C. L.; Karlsson, S. Abnormal angiogenesis but intact hematopoietic potential in TGF-β type I receptor-deficient mice. EMBO J., 2001, 20 (7), 1663-1673.
23. Park, S. O.; Lee, Y. J.; Seki, T.; Hong, K. H.; Fliess, N.; Jiang, Z.; Park, A.; Wu, X.; Kaartinen, V.; Roman, B. L.; Oh, S. P. ALK5- and TGFBR2-independent role of ALK1 in the pathogenesis of hereditary hemorrhagic telangiectasia type 2. Blood, 2008, 111 (2), 633-642.
24. Seki, T.; Hong, K. H.; Oh, S. P. Nonoverlapping expression patterns of ALK1 and ALK5 reveal distinct roles of each receptor in vascular development. Lab. Invest, 2006, 86 (2), 116-129.
25. Carvalho, R. L.; Jonker, L.; Goumans, M. J.; Larsson, J.; Bouwman, P.; Karlsson, S.; ten Dijke, P.; Arthur, H. M.; Mummery, C. L. Defective paracrine signalling by TGF-β in yolk sac vasculature of endoglin mutant mice: a paradigm for hereditary haemorrhagic telangiectasia. Development, 2004, 131 (24), 6237-6247.
26. Goumans, M. J.; Mummery, C. Functional analysis of the TGF-β receptor/Smad pathway through gene ablation in mice. Int. J. Dev. Biol., 2000, 44 (3), 253-265.
27. Arthur, H. M.; Ure, J.; Smith, A. J.; Renforth, G.; Wilson, D. I.; Torsney, E.; Charlton, R.; Parums, D. V.; Jowett, T.; Marchuk, D. A.; Burn, J.; Diamond, A. G. Endoglin, an ancillary TGF-β receptor, is required for extraembryonic angiogenesis and plays a key role in heart development. Dev. Biol., 2000, 217 (1), 42-53.
28. Bourdeau, A.; Dumont, D. J.; Letarte, M. A murine model of hereditary hemorrhagic telangiectasia. J. Clin. Invest., 1999, 104 (10), 1343-1351.
29. Li, D. Y.; Sorensen, L. K.; Brooke, B. S.; Urness, L. D.; Davis, E. C.; Taylor, D. G.; Boak, B. B.; Wendel, D. P. Defective angiogenesis in mice lacking endoglin. Science, 1999, 284 (5419), 1534-1537.
30. Stenvers, K. L.; Tursky, M. L.; Harder, K. W.; Kountouri, N.; Amatayakul-Chantler, S.; Grail, D.; Small, C.; Weinberg, R. A.; Sizeland, A. M.; Zhu, H. J. Heart and liver defects and reduced transforming growth factor β-2 sensitivity in transforming growth factor β-type III receptor-deficient embryos. Mol. Cell Biol., 2003, 23 (12), 4371-4385.
31. Compton, L. A.; Potash, D. A.; Brown, C. B.; Barnett, J. V. Coronary vessel development is dependent on the type III transforming growth factor β-receptor. Circ. Res., 2007, 101 (8), 784-791.
32. Huang, S.; Tang, B.; Usoskin, D.; Lechleider, R. J.; Jamin, S. P.; Li, C.; Anzano, M. A.; Ebendal, T.; Deng, C.; Roberts, A. B. Conditional knockout of the Smad1 gene. Genesis., 2002, 32 (2), 76-79.
33. Lan, Y.; Liu, B.; Yao, H.; Li, F.; Weng, T.; Yang, G.; Li, W.; Cheng, X.; Mao, N.; Yang, X. Essential Role of Endothelial Smad4 in Vascular Remodeling and Integrity. Mol. Cell. Biol., 2007, 27 (21), 7683-7692.
34. Yang, X.; Castilla, L. H.; Xu, X.; Li, C.; Gotay, J.; Weinstein, M.; Liu, P. P.; Deng, C. X. Angiogenesis defects and mesenchymal apoptosis in mice lacking SMAD5. Development, 1999, 126 (8), 1571-1580.
35. Goumans, M. J.; Valdimarsdottir, G.; Itoh, S.; Rosendahl, A.; Sideras, P.; ten Dijke, P. Balancing the activation state of the endothelium via two distinct TGF-β type I receptors. EMBO J., 2002, 21 (7), 1743-1753.
36. Goumans, M. J.; Valdimarsdottir, G.; Itoh, S.; Lebrin, F.; Larsson, J.; Mummery, C.; Karlsson, S.; ten Dijke, P. Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFβ/ALK5 signaling. Mol. Cell, 2003, 12 (4), 817-828.
37. Watabe, T.; Nishihara, A.; Mishima, K.; Yamashita, J.; Shimizu, K.; Miyazawa, K.; Nishikawa, S.; Miyazono, K. TGF-β receptor kinase inhibitor enhances growth and integrity of embryonic stem cell-derived endothelial cells. J. Cell Biol., 2003, 163 (6), 1303-1311.
38. Birukova, A. A.; Adyshev, D.; Gorshkov, B.; Birukov, K. G.; Verin, A. D. ALK5 and Smad4 are involved in TGF-β1-induced pulmonary endothelial permeability. FEBS Lett., 2005, 579 (18), 4031-4037.
39. Rudini, N.; Felici, A.; Giampietro, C.; Lampugnani, M.; Corada, M.; Swirsding, K.; Garre, M.; Liebner, S.; Letarte, M.; ten Dijke, P.; Dejana, E. VE-cadherin is a critical endothelial regulator of TGF-β signalling. EMBO J., 2008, 27 (7), 993-1004.
40. David, L.; Mallet, C.; Vailhe, B.; Lamouille, S.; Feige, J. J.; Bailly, S. Activin receptor-like kinase 1 inhibits human microvascular endothelial cell migration: potential roles for JNK and ERK. J. Cell Physiol., 2007, 213 (2), 484-489.
41. Lamouille, S.; Mallet, C.; Feige, J. J.; Bailly, S. Activin receptorlike kinase 1 is implicated in the maturation phase of angiogenesis. Blood, 2002, 100 (13), 4495-4501.
42. Mallet, C.; Vittet, D.; Feige, J. J.; Bailly, S. TGFβ1 induces vasculogenesis and inhibits angiogenic sprouting in an embryonic stem cell differentiation model: respective contribution of ALK1 and ALK5. Stem Cells, 2006, 24 (11), 2420-2427.
43. Cheifetz, S.; Hernandez, H.; Laiho, M.; ten Dijke, P.; Iwata, K. K.; Massague, J. Distinct transforming growth factor-β (TGF-β) receptor subsets as determinants of cellular responsiveness to three TGF-β isoforms. J Biol. Chem., 1990, 265 (33), 20533-20538.
44. Wong, S. H.; Hamel, L.; Chevalier, S.; Philip, A. Endoglin expression on human microvascular endothelial cells - Association with betaglycan and formation of higher order complexes with TGF-β signalling receptors. Eur. J. Biochem., 2000, 267 (17), 5550-5560.
45. Bot, P. T.; Hoefer, I. E.; Sluijter, J. P.; van Vliet, P.; Smits, A. M.; Lebrin, F.; Moll, F.; de Vries, J. P.; Doevendans, P.; Piek, J. J.; Pasterkamp, G.; Goumans, M. J. Increased expression of the transforming growth factor-β signaling pathway, endoglin, and early growth response-1 in stable plaques. Stroke, 2009, 40 (2), 439-447.
46. Lebrin, F.; Goumans, M. J.; Jonker, L.; Carvalho, R. L.; Valdimarsdottir, G.; Thorikay, M.; Mummery, C.; Arthur, H. M.; ten Dijke, P. Endoglin promotes endothelial cell proliferation and TGF-β/ALK1 signal transduction. EMBO J., 2004, 23 (20), 4018-4028.
47. Lastres, P.; Letamendia, A.; Zhang, H.; Rius, C.; Almendro, N.; Raab, U.; Lopez, L. A.; Langa, C.; Fabra, A.; Letarte, M.; Bernabeu, C. Endoglin modulates cellular responses to TGF-β-1. J. Cell Biol., 1996, 133 (5), 1109-1121.
48. Obreo, J.; Diez-Marques, L.; Lamas, S.; Duwell, A.; Eleno, N.; Bernabeu, C.; Pandiella, A.; Lopez-Novoa, J. M.; Rodriguez- Barbero, A. Endoglin expression regulates basal and TGF-β-1- induced extracellular matrix synthesis in cultured L6E9 myoblasts. Cell Physiol. Biochem., 2004, 14 (4-6), 301-310.
49. Blanco, F. J.; Santibanez, J. F.; Guerrero-Esteo, M.; Langa, C.; Vary, C. P.; Bernabeu, C. Interaction and functional interplay between endoglin and ALK-1, two components of the endothelial transforming growth factor-β receptor complex. J. Cell Physiol., 2005, 204 (2), 574-584.
50. Jerkic, M.; Rodriguez-Barbero, A.; Prieto, M.; Toporsian, M.; Pericacho, M.; Rivas-Elena, J. V.; Obreo, J.; Wang, A.; Perez- Barriocanal, F.; Arevalo, M.; Bernabeu, C.; Letarte, M.; Lopez- Novoa, J. M. Reduced angiogenic responses in adult Endoglin heterozygous mice. Cardiovasc. Res., 2006, 69 (4), 845-854.
51. Li, C.; Issa, R.; Kumar, P.; Hampson, I. N.; Lopez-Novoa, J. M.; Bernabeu, C.; Kumar, S. CD105 prevents apoptosis in hypoxic endothelial cells. J. Cell Sci., 2003, 116 (Pt 13), 2677-2685.
52. Perez-Gomez, E.; Eleno, N.; Lopez-Novoa, J. M.; Ramirez, J. R.; Velasco, B.; Letarte, M.; Bernabeu, C.; Quintanilla, M. Characterization of murine S-endoglin isoform and its effects on tumor development. Oncogene, 2005, 24 (27), 4450-4461.
53. Velasco, S.; Alvarez-Munoz, P.; Pericacho, M.; ten Dijke, P.; Bernabeu, C.; Lopez-Novoa, J. M.; Rodriguez-Barbero, A. L- and S-endoglin differentially modulate TGF- β1 signaling mediated by ALK1 and ALK5 in L6E9 myoblasts. J. Cell Sci., 2008, 121 (Pt 6), 913-919.
54. Blanco, F. J.; Grande, M. T.; Langa, C.; Oujo, B.; Velasco, S.; Rodriguez-Barbero, A.; Perez-Gomez, E.; Quintanilla, M.; Lopez- Novoa, J. M.; Bernabeu, C. S-endoglin expression is induced in senescent endothelial cells and contributes to vascular pathology. Circ. Res., 2008, 103(12), 1383-1392.
55. Hawinkels, L. J.; Kuiper, P.; Wiercinska, E.; Verspaget, H. W.; Liu, Z.; Pardali, E.; Sier, C. F.; ten Dijke, P. Matrix metalloproteinase-14 (MT1-MMP)-mediated endoglin shedding inhibits tumor angiogenesis. Cancer Res., 2010, 70(10), 4141-4150.
56. Levine, R. J.; Lam, C.; Qian, C.; Yu, K. F.; Maynard, S. E.; Sachs, B. P.; Sibai, B. M.; Epstein, F. H.; Romero, R.; Thadhani, R.; Karumanchi, S. A.; The CPEP study group. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N. Engl. J. Med., 2006, 355(10), 992-1005.
57. Li, C. Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer. Int. J. Cancer, 2000, 89(2), 122-126.
58. Bobik, A. Transforming growth factor-β and vascular disorders. Arterioscler. Thromb. Vasc. Biol., 2006, 26(8), 1712-1720.
59. Owens, G. K. Regulation of differentiation of vascular smooth muscle cells. Physiol Rev., 1995, 75 (3), 487-517.
60. Hungerford, J. E.; Owens, G. K.; Argraves, W. S.; Little, C. D. Development of the aortic vessel wall as defined by vascular smooth muscle and extracellular matrix markers. Dev. Biol., 1996, 178 (2), 375-392.
61. Ding, R.; Darland, D. C.; Parmacek, M. S.; D'Amore, P. A. Endothelial-mesenchymal interactions in vitro reveal molecular mechanisms of smooth muscle/pericyte differentiation. Stem Cells Dev., 2004, 13 (5), 509-520.
62. Yamashita, H.; Shimizu, A.; Kato, M.; Nishitoh, H.; Ichijo, H.; Hanyu, A.; Morita, I.; Kimura, M.; Makishima, F.; Miyazono, K. Growth/differentiation factor-5 induces angiogenesis in vivo. Exp. Cell Res., 1997, 235 (1), 218-226.
63. Langenfeld, E. M.; Langenfeld, J. Bone morphogenetic protein-2 stimulates angiogenesis in developing tumors. Mol. Cancer Res., 2004, 2 (3), 141-149.
64. Raida, M.; Clement, J. H.; Leek, R. D.; Ameri, K.; Bicknell, R.; Niederwieser, D.; Harris, A. L. Bone morphogenetic protein 2 (BMP-2) and induction of tumor angiogenesis. J. Cancer Res. Clin. Oncol., 2005, 131(11), 741-750.
65. David, L.; Feige, J. J.; Bailly, S. Emerging role of bone morphogenetic proteins in angiogenesis. Cytokine Growth Factor Rev., 2009, 20(3), 203-212.
66. Valdimarsdottir, G.; Goumans, M. J.; Rosendahl, A.; Brugman, M.; Itoh, S.; Lebrin, F.; Sideras, P.; ten Dijke, P. Stimulation of Id1 expression by bone morphogenetic protein is sufficient and necessary for bone morphogenetic protein-induced activation of endothelial cells. Circulation, 2002, 106(17), 2263-2270.
67. Suzuki, Y.; Montagne, K.; Nishihara, A.; Watabe, T.; Miyazono, K. BMPs promote proliferation and migration of endothelial cells via stimulation of VEGF-A/VEGFR2 and angiopoietin-1/Tie2 signalling. J. Biochem., 2008, 143(2), 199-206.
68. Brown, M. A.; Zhao, Q.; Baker, K. A.; Naik, C.; Chen, C.; Pukac, L.; Singh, M.; Tsareva, T.; Parice, Y.; Mahoney, A.; Roschke, V.; Sanyal, I.; Choe, S. Crystal Structure of BMP-9 and functional interactions with pro-region and receptors. J. Biolog. Chem., 2005, 280 (26), 25111-25118.
69. Scharpfenecker, M.; van Dinther, M.; Liu, Z.; van Bezooijen, R. L.; Zhao, Q.; Pukac, L.; Lowik, C. W.; ten Dijke, P. BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis. J. Cell Sci., 2007, 120 (Pt 6), 964-972.
70. David, L.; Mallet, C.; Mazerbourg, S.; Feige, J. J.; Bailly, S. Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. Blood, 2007, 109 (5), 1953-1961.
71. Upton, P. D.; Davies, R. J.; Trembath, R. C.; Morrell, N. W. Bone morphogenetic protein (BMP) and activin type II receptors balance BMP9 signals mediated by activin receptor-like kinase-1 in human pulmonary artery endothelial cells. J. Biolog. Chem., 2009, 284 (23), 15794-15804.
72. David, L.; Mallet, C.; Keramidas, M.; Lamande, N.; Gasc, J. M.; Dupuis-Girod, S.; Plauchu, H.; Feige, J. J.; Bailly, S. Bone morphogenetic protein-9 is a circulating vascular quiescence factor. Circ. Res., 2008, 102 (8), 914-922.
73. Suzuki, Y.; Ohga, N.; Morishita, Y.; Hida, K.; Miyazono, K.; Watabe, T. BMP-9 induces proliferation of multiple types of endothelial cells in vitro and in vivo. J. Cell Sci., 2010, 123(10), 1684-1692.
74. Willette, R. N.; Gu, J. L.; Lysko, P. G.; Anderson, K. M.; Minehart, H.; Yue, T. BMP-2 gene expression and effects on human vascular smooth muscle cells. J. Vasc. Res., 1999, 36(2), 120-125.
75. Hansmann, G.; de Jesus Perez, V. A.; Alastalo, T. P.; Alvira, C. M.; Guignabert, C.; Bekker, J. M.; Schellong, S.; Urashima, T.; Wang, L.; Morrell, N. W.; Rabinovitch, M. An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension. J. Clin. Invest., 2008, 118(5), 1846-1857.
76. Dorai, H.; Vukicevic, S.; Sampath, T. K. Bone morphogenetic protein-7 (osteogenic protein-1) inhibits smooth muscle cell proliferation and stimulates the expression of markers that are characteristic of SMC phenotype in vitro. J. Cell Physiol., 2000, 184(1), 37-45.
77. Lagna, G.; Nguyen, P. H.; Ni, W.; Hata, A. BMP-dependent activation of caspase-9 and caspase-8 mediates apoptosis in pulmonary artery smooth muscle cells. Am. J. Physiol. Lung Cell Mol. Physiol., 2006, 291(5), L1059-L1067.
78. Abdalla, S. A.; Letarte, M. Hereditary haemorrhagic telangiectasia: current views on genetics and mechanisms of disease. J. Med. Genet., 2006, 43(2), 97-110.
79. McAllister, K. A.; Grogg, K. M.; Johnson, D. W.; Gallione, C. J.; Baldwin, M. A.; Jackson, C. E.; Helmbold, E. A.; Markel, D. S.; McKinnon, W. C.; Murrell, J. Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat. Genet., 1994, 8 (4), 345-351.
80. Johnson, D. W.; Berg, J. N.; Baldwin, M. A.; Gallione, C. J.; Marondel, I.; Yoon, S. J.; Stenzel, T. T.; Speer, M.; Pericak-Vance, M. A.; Diamond, A.; Guttmacher, A. E.; Jackson, C. E.; Attisano, L.; Kucherlapati, R.; Porteous, M. E.; Marchuk, D. A. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat. Genet., 1996, 13 (2), 189-195.
81. Gallione, C. J.; Richards, J. A.; Letteboer, T. G.; Rushlow, D.; Prigoda, N. L.; Leedom, T. P.; Ganguly, A.; Castells, A.; Ploos van Amstel, J. K.; Westermann, C. J.; Pyeritz, R. E.; Marchuk, D. A. SMAD4 mutations found in unselected HHT patients. J. Med. Genet., 2006, 43(10), 793-797.
82. Bourdeau, A.; Faughnan, M. E.; McDonald, M. L.; Paterson, A. D.; Wanless, I. R.; Letarte, M. Potential role of modifier genes influencing transforming growth factor-β1 levels in the development of vascular defects in endoglin heterozygous mice with hereditary hemorrhagic telangiectasia. Am. J. Pathol., 2001, 158(6), 2011-2020.
83. Simonds, J.; Miller, F.; Mandel, J.; Davidson, T. M. The effect of bevacizumab (Avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope, 2009, 119(5), 988-992.
84. Lebrin, F.; Srun, S.; Raymond, K.; Martin, S.; van den Brink, S.; Freitas, C.; Breant, C.; Mathivet, T.; Larrivee, B.; Thomas, J. L.; Arthur, H. M.; Westermann, C. J.; Disch, F.; Mager, J. J.; Snijder, R. J.; Eichmann, A.; Mummery, C. L. Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. Nat. Med., 2010, 16(4), 420-428.
85. Sibai, B. M. Preeclampsia as a cause of preterm and late preterm (near-term) births. Semin. Perinatol., 2006, 30(1), 16-19.
86. Venkatesha, S.; Toporsian, M.; Lam, C.; Hanai, J.; Mammoto, T.; Kim, Y. M.; Bdolah, Y.; Lim, K. H.; Yuan, H. T.; Libermann, T. A.; Stillman, I. E.; Roberts, D.; D'Amore, P. A.; Epstein, F. H.; Sellke, F. W.; Romero, R.; Sukhatme, V. P.; Letarte, M.; Karumanchi, S. A. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat. Med., 2006, 12(6), 642-649.
87. Cool, C. D.; Stewart, J. S.; Werahera, P.; Miller, G. J.; Williams, R. L.; Voelkel, N. F.; Tuder, R. M. Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. Am. J. Pathol., 1999, 155(2), 411-419.
88. Atkinson, C.; Stewart, S.; Upton, P. D.; Machado, R.; Thomson, J. R.; Trembath, R. C.; Morrell, N. W. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of Type II bone morphogenetic protein receptor. Circulation, 2002, 105 (14), 1672-1678.
89. Lane, K. B.; Machado, R. D.; Pauciulo, M. W.; Thomson, J. R.; Phillips, J. A., III; Loyd, J. E.; Nichols, W. C.; Trembath, R. C. Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension. Nat. Genet., 2000, 26 (1), 81-84.
90. Machado, R. D.; Aldred, M. A.; James, V.; Harrison, R. E.; Patel, B.; Schwalbe, E. C.; Gruenig, E.; Janssen, B.; Koehler, R.; Seeger, W.; Eickelberg, O.; Olschewski, H.; Elliott, C. G.; Glissmeyer, E.; Carlquist, J.; Kim, M.; Torbicki, A.; Fijalkowska, A.; Szewczyk, G.; Parma, J.; Abramowicz, M. J.; Galie, N.; Morisaki, H.; Kyotani, S.; Nakanishi, N.; Morisaki, T.; Humbert, M.; Simonneau, G.; Sitbon, O.; Soubrier, F.; Coulet, F.; Morrell, N. W.; Trembath, R. C. Mutations of the TGF-β type II receptor BMPR2 in pulmonary arterial hypertension. Hum. Mutat., 2006, 27 (2), 121-132.
91. Ribatti, D.; Nico, B.; Crivellato, E.; Roccaro, A. M.; Vacca, A. The history of the angiogenic switch concept. Leukemia, 2007, 21 (1), 44-52.
92. Ikushima, H.; Miyazono, K. TGFβ signalling: a complex web in cancer progression. Nat. Rev. Cancer, 2010, 10 (6), 415-424.
93. Hasegawa, Y.; Takanashi, S.; Kanehira, Y.; Tsushima, T.; Imai, T.; Okumura, K. Transforming growth factor-β1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma. Cancer, 2001, 91 (5), 964-971.
94. Tuxhorn, J. A.; McAlhany, S. J.; Yang, F.; Dang, T. D.; Rowley, D. R. Inhibition of transforming growth factor-β activity decreases angiogenesis in a human prostate cancer-reactive stroma xenograft model. Cancer Res., 2002, 62 (21), 6021-6025.
95. Sanchez-Elsner, T.; Botella, L. M.; Velasco, B.; Corbi, A.; Attisano, L.; Bernabeu, C. Synergistic cooperation between hypoxia and transforming growth factor-β pathways on human vascular endothelial growth factor gene expression. J. Biol. Chem., 2001, 276 (42), 38527-38535.
96. Kang, Y.; Siegel, P. M.; Shu, W.; Drobnjak, M.; Kakonen, S. M.; Cordon-Cardo, C.; Guise, T. A.; Massague, J. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell, 2003, 3 (6), 537-549.
97. Derynck, R.; Akhurst, R. J.; Balmain, A. TGF-β signaling in tumor suppression and cancer progression. Nat. Genet., 2001, 29 (2), 117-129.
98. Schwarte-Waldhoff, I. Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis. Proc. Natl Acad. Sci. USA, 2000, 97, 9624-9629.
99. Komuro, A. Diffuse-type gastric carcinoma: progression, angiogenesis, and transforming growth factor β signaling. J. Natl. Cancer Inst., 2009, 101, 592-604.
100. Kiyono, K. c-Ski overexpression promotes tumor growth and angiogenesis through inhibition of transforming growth factor-β signaling in diffuse-type gastric carcinoma. Cancer Sci., 2009, 100, 1809-1816.
101. Fonsatti, E.; Del Vecchio, L.; Altomonte, M.; Sigalotti, L.; Nicotra, M. R.; Coral, S.; Natali, P. G.; Maio, M. Endoglin: An accessory component of the TGF-β-binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies. J. Cell. Physiol., 2001, 188 (1), 1-7.
102. Wikstrom, P.; Lissbrandt, I. F.; Stattin, P.; Egevad, L.; Bergh, A. Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate, 2002, 51 (4), 268-275.
103. Burrows, F. J.; Derbyshire, E. J.; Tazzari, P. L.; Amlot, P.; Gazdar, A. F.; King, S. W.; Letarte, M.; Vitetta, E. S.; Thorpe, P. E. Upregulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin. Cancer Res., 1995, 1 (12), 1623-1634.
104. Miller, D. W.; Graulich, W.; Karges, B.; Stahl, S.; Ernst, M.; Ramaswamy, A.; Sedlacek, H. H.; Muller, R.; Adamkiewicz, J. Elevated expression of endoglin, a component of the TGF-β- receptor complex, correlates with proliferation of tumor endothelial cells. Intl. J. Cancer, 1999, 81 (4), 568-572.
105. Fonsatti, E.; Jekunen, A. P.; Kairemo, K. J. A.; Coral, S.; Snellman, M.; Nicotra, M. R.; Natali, P. G.; Altomonte, M.; Maio, M. Endoglin is a suitable target for efficient imaging of solid tumors: in vivo evidence in a canine mammary carcinoma model. Clin. Cancer Res., 2000, 6 (5), 2037-2043.
106. Wang, J. M.; Kumar, S.; Pye, D.; Vanagthoven, A. J.; Krupinski, J.; Hunter, R. D. A Monoclonal-antibody detects heterogeneity in vascular endothelium of tumors and normal-tissues. Intl. J. Cancer, 1993, 54 (3), 363-370.
107. Wang, J. M.; Kumar, S.; Pye, D.; Haboubi, N.; Al-Nakib, L. Breast carcinoma: comparative study of tummor vasculature using two endothelial cell markers. J. Natl. Cancer Inst., 1994, 86 (5), 386-389.
108. Kumar, S.; Ghellal, A.; Li, C.; Byrne, G.; Haboubi, N.; Wang, J. M.; Bundred, N. Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis. Cancer Res., 1999, 59 (4), 856-861.
109. Shariat, S. F.; Karam, J. A.; Walz, J.; Roehrborn, C. G.; Montorsi, F.; Margulis, V.; Saad, F.; Slawin, K. M.; Karakiewicz, P. I. Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers. Clin. Cancer Res., 2008, 14 (12), 3785-3791.
110. Kano, M. R.; Bae, Y.; Iwata, C.; Morishita, Y.; Yashiro, M.; Oka, M.; Fujii, T.; Komuro, A.; Kiyono, K.; Kaminishi, M.; Hirakawa, K.; Ouchi, Y.; Nishiyama, N.; Kataoka, K.; Miyazono, K. Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-β signaling. Proc. Natl. Acad. Sci. USA, 2007, 104 (9), 3460-3465.
111. She, X. W.; Matsuno, F.; Harada, N.; Tsai, H.; Seon, B. K. Synergy between anti-endoglin (CD105) monoclonal antibodies and TGF-β in suppression of growth of human endothelial cells. Intl. J. Cancer, 2004, 108 (2), 251-257.
112. Korn, T.; Muller, R.; Kontermann, R. E. Bispecific single-chain diabody-mediated killing of endoglin-positive endothelial cells by cytotoxic T lymphocytes. J. Immunother., 2004, 27 (2), 99-106.
113. Volkel, T.; Holig, P.; Merdan, T.; Muller, R.; Kontermann, R. E. Targeting of immunoliposomes to endothelial cells using a singlechain Fv fragment directed against human endoglin (CD105). Biochim. Biophys. Acta, 2004, 1663 (1-2), 158-166.
114. Ahmadvand, D.; Rasaee, M. J.; Rahbarizadeh, F.; Mohammadi, M. Production and characterization of a high-affinity nanobody against human endoglin. Hybridoma (Larchmt.), 2008, 27 (5), 353-360.
115. Matsuno, F.; Haruta, Y.; Kondo, M.; Tsai, H.; Barcos, M.; Seon, B. K. Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new antiendoglin monoclonal antibodies. Clin. Cancer Res., 1999, 5 (2), 371-382.
116. Seon, B. K.; Matsuno, F.; Haruta, Y.; Kondo, M.; Barcos, M. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin. Clin. Cancer Res., 1997, 3(7), 1031-1044.
117. Tabata, M.; Kondo, M.; Haruta, Y.; Seon, B. K. Antiangiogenic radioimmunotherapy of human solid tumors in SCID mice using I- 125-labeled anti-endoglin monoclonal antibodies. Intl. J. Cancer, 1999, 82(5), 737-742.
118. Tsujie, M.; Tsujie, T.; Toi, H.; Uneda, S.; Shiozaki, K.; Tsai, H.; Seon, B. K. Anti-tumor activity of an anti-endoglin monoclonal antibody is enhanced in immunocompetent mice. Intl. J. Cancer, 2008, 122(10), 2266-2273.
119. Uneda, S.; Toi, H.; Tsujie, T.; Tsujie, M.; Harada, N.; Tsai, H.; Seon, B. K. Anti-endoglin monoclonal antibodies are effective for suppressing metastasis and the primary tumors by targeting tumor vasculature. Int. J. Cancer, 2009, 125 (6), 1446-1453.
120. Takahashi, N.; Haba, A.; Matsuno, F.; Seon, B. K. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide. Cancer Res., 2001, 61 (21), 7846-7854.
121. Tan, G. H.; Huang, F. Y.; Wang, H.; Huang, Y. H.; Lin, Y. Y.; Li, Y. N. Immunotherapy of hepatoma with a monoclonal antibody against murine endoglin. World J. Gastroenterol., 2007, 13 (17), 2479-2483.
122. Rosen, L.; Gordon, M. S.; Hurwitz, H. I.; Wong, M. K.; Adams, B. J.; Alvarez, D.; Seon, B. K.; Leigh, B. R.; Theuer, C. P. Early evidence of tolerability and clinical activity from a phase I study of TRC105 (anti-CD105 antibody) in patients with advanced refractory cancer. J. Clin. Oncol., (Meeting Abstracts), 2009, 27 (15S), 3518.
123. Mendelson, D. S.; Gordon, M. S.; Rosen, L.; Hurwitz, H. I.; Wong, M. K.; Adams, B. J.; Alvarez, D.; Seon, B. K.; Theuer, C. P.; Leigh, B. R. Phase I study of TRC105 (anti-CD105 [endoglin] antibody) therapy in patients with advanced refractory cancer. J. Clin. Oncol., (Meeting Abstracts), 2010, 28 (15S), 3013.
124. Bredow, S.; Lewin, M.; Hofmann, B.; Marecos, E.; Weissleder, R. Imaging of tumour neovasculature by targeting the TGF-β binding receptor endoglin. Euro. J. Cancer, 2000, 36 (5), 675-681.
125. Costello, B.; Chenggang, L. G.; Duff, S.; Butterworth, D.; Khan, A.; Perkins, M.; Owens, S.; Al-Mowallad, A. F.; O'Dwyer, S. O.; Kumar, S. Perfusion of Tc-99(m)-labeled CD105 Mab into kidneys from patients with renal carcinoma suggests that CD105 is a promising vascular target. Intl. J. Cancer, 2004, 109 (3), 436-441.
126. Mitchell, D.; Pobre, E. G.; Mulivor, A. W.; Grinberg, A. V.; Castonguay, R.; Monnell, T. E.; Solban, N.; Ucran, J. A.; Pearsall, R. S.; Underwood, K. W.; Seehra, J.; Kumar, R. ALK1-Fc inhibits multiple mediators of angiogenesis and suppresses tumor growth. Mol. Cancer Ther., 2010, 9 (2), 379-388.
127. Cunha, S. I.; Pardali, E.; Thorikay, M.; Anderberg, C.; Hawinkels, L.; Goumans, M. J.; Seehra, J.; Heldin, C. H.; ten Dijke, P.; Pietras, K. Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis. J. Exp. Med., 2010, 207 (1), 85-100.
128. Hu-Lowe, D.; Wickman, G.; Jiang, X.; Kraynov, E.; Wang, J.; Amundson, K.; Simmons, B.; Liang, S.; Chen, E.; Karlicek, S.; Thompson, J.; Swanson, T.; Yan, Z.; Li, G.; Los, G.; Hostomsky, Z.; Casperson, G.; Bender, S.; North, M. Anti-angiogenesis through inhibition of ALK-1 (activin-like receptor kinase 1) with a fully human monoclonal antibody PF-03446962. Proceedings of the 100th Annual Meeting of the American Association for Cancer Research, 2009.
129. Mancuso, P.; Shalinsky, D. R.; Calleri, A.; Quarna, J.; Antoniotti, P.; Jilani, I.; Hu-Lowe, D.; Jiang, X.; Gallo-Stampino, C.; Bertolini, F. Evaluation of ALK-1 expression in circulating endothelial cells (CECs) as an exploratory biomarker for PF- 03446962 undergoing phase I trial in cancer patients. J. Clin. Oncol., (Meeting Abstracts), 2009, 27 (15s), (suppl; abstr 3573).
130. Goff, L. W.; De Braud, F. G.; Cohen, R. B.; Berlin, J.; Noberasco, C.; Borghaei, H.; Wang, E.; Hu-Lowe, D.; Levin, W. J.; Gallo- Stampino, C. Phase I study of PF-03446962, a fully human mab against ALK 1, a TGF-β receptor involved in tumor angiogenesis. J. Clin. Oncol., (Meeting Abstracts), 2010, 28 (15s), (suppl; abstr 3034).